|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
DE69232137T2
(de)
|
1991-11-25 |
2002-05-29 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
EP1958962A3
(en)
|
1997-06-12 |
2013-05-01 |
Novartis International Pharmaceutical Ltd. |
Artificial antibody polypeptides
|
|
CA2386270A1
(en)
|
1999-10-15 |
2001-04-26 |
University Of Massachusetts |
Rna interference pathway genes as tools for targeted genetic interference
|
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
|
CA2406864A1
(en)
|
2000-02-24 |
2001-08-30 |
Life Technologies Corporation |
Simultaneous stimulation and concentration of cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
AU2001275474A1
(en)
|
2000-06-12 |
2001-12-24 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
WO2004094642A2
(en)
|
2003-04-24 |
2004-11-04 |
Fondazione Centro San Raffaele Del Monte Tabor |
Lentiviral vectors carrying synthetic bi-directional promoters and uses thereof
|
|
AU2005250408B2
(en)
|
2004-05-27 |
2010-09-23 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
US20070036773A1
(en)
|
2005-08-09 |
2007-02-15 |
City Of Hope |
Generation and application of universal T cells for B-ALL
|
|
GB0603081D0
(en)
|
2006-02-15 |
2006-03-29 |
Dynal Biotech Asa Oslo |
Method
|
|
EP2126054B1
(en)
|
2007-01-31 |
2016-07-06 |
Yeda Research And Development Company Limited |
Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
CA2993567C
(en)
|
2010-07-21 |
2022-06-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of a t-cell receptor gene
|
|
EP2694549B1
(en)
|
2011-04-08 |
2018-08-15 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
|
|
EP3241902B1
(en)
|
2012-05-25 |
2018-02-28 |
The Regents of The University of California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
|
AU2013359262C1
(en)
|
2012-12-12 |
2021-05-13 |
Massachusetts Institute Of Technology |
CRISPR-Cas component systems, methods and compositions for sequence manipulation
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
CA2894684A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
|
|
ES2918501T3
(es)
*
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
US10287354B2
(en)
*
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
US20170081411A1
(en)
*
|
2014-03-15 |
2017-03-23 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
EP3593812A3
(en)
*
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
CA2958200A1
(en)
*
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
|
|
EP3298041A1
(en)
|
2015-05-18 |
2018-03-28 |
Numab Therapeutics AG |
Novel treatment methods based on multifunctional molecules
|
|
CN105384825B
(zh)
*
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
KR20200068750A
(ko)
*
|
2016-04-01 |
2020-06-15 |
카이트 파마 인코포레이티드 |
키메라 수용체 및 그의 사용 방법
|
|
WO2018075820A2
(en)
*
|
2016-10-20 |
2018-04-26 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
|
WO2018106993A1
(en)
*
|
2016-12-09 |
2018-06-14 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Tlr9-binding chimeric antigen receptors
|
|
CN108276493B
(zh)
*
|
2016-12-30 |
2023-11-14 |
南京传奇生物科技有限公司 |
一种嵌合抗原受体及其应用
|
|
JP7618192B2
(ja)
|
2017-03-28 |
2025-01-21 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
移植された組織を拒絶反応から保護するための方法
|
|
CA3076261A1
(en)
|
2017-09-19 |
2019-03-28 |
Admare Vintageco1 Investments Ltd. |
Anti-hla-a2 antibodies and methods of using the same
|